Hoth Therapeutics’ topical therapy shines in cancer toxicity trial
Achieves 100 percent response in phase II data highlighting HT-001's potential as a supportive oncology treatment to address a common EGFR therapy burden.
List view / Grid view
Achieves 100 percent response in phase II data highlighting HT-001's potential as a supportive oncology treatment to address a common EGFR therapy burden.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Findings from the interim clinical study showed that the gel formulation enhanced quality of life in over half of cancer patients.